Mirum Pharmaceuticals, Inc.
LIVMARLI
Alagille syndrome
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on LIVMARLI for Alagille syndrome is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Received FDA approval ... of LIVMARLI tablets for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).”